IPM Take
Europe is not facing untreatable gonorrhoea yet. It is being shown how that future begins.
ECDC says ceftriaxone-resistant strains have been detected in an increasing number of European countries, with domestic transmission documented during 2025 and 2026. Every resistant case treated successfully is reassuring. Every resistant case missed by culture, susceptibility testing or test-of-cure is an opportunity for the problem to become established.
Executive Summary
ECDC published a rapid risk assessment on an upsurge of ceftriaxone-resistant Neisseria gonorrhoeae in the EU/EEA and the United Kingdom. Reports came from 11 countries, and evidence now includes local European transmission rather than travel-associated importation alone. More than 106,000 gonorrhoea cases were notified in the EU/EEA in 2024, the highest annual number since enhanced surveillance began in 2009.
Why it matters
- Clinicians: Need timely diagnosis, appropriate treatment, test-of-cure and partner management, particularly where resistance or treatment failure is suspected.
- Diagnostics / pathology: Need culture, antimicrobial susceptibility testing and genomic surveillance capacity alongside widely used molecular tests.
- Public authorities: Need coordinated reporting and non-stigmatising prevention that reaches sexual networks without driving infection away from care.
A first-line antibiotic is only first-line while it still works.
Ceftriaxone remains the central treatment for gonorrhoea in Europe. ECDC’s new assessment is therefore not a technical footnote about a handful of unusual laboratory results. It is an early warning about the durability of one of the few therapies on which routine care still depends.
Resistant infections have often been linked to travel, particularly to South-East Asia. That route remains important. What changed is the evidence of domestic transmission in Europe during 2025 and 2026. Resistant strains are not simply arriving, being detected and disappearing. Some are moving locally.
That matters because gonorrhoea is already common. EU/EEA countries reported more than 106,000 cases in 2024, the highest annual total since enhanced surveillance began in 2009. Resistance does not need to dominate every infection to create a clinical problem. It needs only to become established inside networks where diagnosis is delayed, treatment is empirical and follow-up is inconsistent.
The diagnostic architecture is part of the vulnerability. Nucleic-acid amplification tests make infection easier to detect, but they do not automatically show which antibiotics will work. Culture and antimicrobial susceptibility testing remain essential when resistance is suspected. Genomic surveillance can then identify whether cases are linked, imported or spreading domestically. A system that diagnoses infection but cannot characterise resistance sees only half the threat.
ECDC says all known ceftriaxone-resistant cases in the current assessment were ultimately treated successfully. That is good news, but it should not become permission for complacency. Success depended on cases being found, investigated and followed. The harder question is how many infections never reach culture, how many patients do not return for a test-of-cure and how often partners remain outside the pathway.
Public communication must also be precise. Stigma is not a control measure. Moralising about sexual behaviour discourages testing and weakens partner notification. Effective prevention means accessible services, confidential care, clear advice and enough laboratory capacity to detect the infections that ordinary treatment may not cure.
The politics of antimicrobial resistance often focuses on future drug pipelines. Those pipelines matter. But Europe also has to protect ceftriaxone now. That requires surveillance that reaches routine practice, not only reference laboratories; clinicians who know when to obtain cultures; and systems that can act on treatment failure before one cluster becomes a new baseline.
For IPM, the warning is simple. Resistance becomes a crisis gradually, then clinically. The time to build the diagnostic and referral pathway is while treatment options still exist.
